Spiperone
From Wikipedia, the free encyclopedia
 |
|
|---|---|
| Systematic (IUPAC) name | |
| 8-[4-(4-fluorophenyl)-4-oxo-butyl]-1-phenyl-1,3,8-triazaspiro[4.5]decan-4-one | |
| Clinical data | |
| AHFS/Drugs.com | International Drug Names |
| Pregnancy cat. | ? |
| Legal status | ? |
| Routes | Oral |
| Pharmacokinetic data | |
| Metabolism | Hepatic |
| Excretion | Renal |
| Identifiers | |
| CAS number | 749-02-0  |
| ATC code | None |
| PubChem | CID 5265 |
| IUPHAR ligand | 99 |
| ChemSpider | 5075 |
| UNII | 4X6E73CJ0Q |
| KEGG | D01051 |
| ChEBI | CHEBI:9233 |
| ChEMBL | CHEMBL267930 |
| Chemical data | |
| Formula | C23H26FN3O2 |
| Mol. mass | 395.47 g/mol |
|
|
|
|
 (what is this?) (verify) |
|
Spiperone (Spiroperidol, Spiropitan) is a psychoactive drug and research chemical belonging to the butyrophenone chemical class.[1] It functions as a 5-HT1A, 5-HT2A, 5-HT7, and D2 receptor antagonist, and has been used to identify these receptors when labeled with tritium. It has negligible affinity for the 5-HT2C receptor. Additionally, spiperone was identified by compound screening to be an activator of Ca2+ activated Cl- channels (CaCCs), thus a potential target for therapy of cystic fibrosis.[2]
N-Methylspiperone (NMSP) is a derivate of spiperone that is used to study the dopamine and serotonin neurotransmitter system. Labeled with the radioisotope carbon-11, it can be used for positron emission tomography.[3]
[edit] References
- ^ Zheng LT, Hwang J, Ock J, Lee MG, Lee WH, Suk K (September 2008). "The antipsychotic spiperone attenuates inflammatory response in cultured microglia via the reduction of proinflammatory cytokine expression and nitric oxide production". J. Neurochem. 107 (5): 1225–35. doi:10.1111/j.1471-4159.2008.05675.x. PMID 18786164.
- ^ Liang L, Macdonald KD, Schwiebert EM, Zeitlin PL, Guggino WB. (october 2008). "Spiperone, Identified through Compound Screening, Activates Calcium Dependent Chloride Secretion in the Airway". Am J Physiol Cell Physiol 296 (1): C131–41. doi:10.1152/ajpcell.00346.2008. PMID 18987251.
- ^ Bengt Andree and others (August 1998). "Positron Emission Tomographic Analysis of Dose-dependent MDL-100,907 Binding to 5-Hydroxtryptamine-2A Receptors in the Human Brain". Journal of Clinical Psychopharmacology 18 (4): 313–323.
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
